Viridian Therapeutics price target lowered to $36 from $40 at Truist

1 hour ago 1

Skip to navigation Skip to main contented Skip to close file

TipRanks

Thu, April 9, 2026 astatine 7:32 AM CDT 1 min read

Truist lowered the firm’s terms people connected Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy standing connected the shares arsenic portion of a broader probe enactment previewing Q1 net successful Biotech. Reactivity to regulatory and argumentation shifts crossed the assemblage continues to ease, and the steadfast besides notes a caller pickup successful woody activity, which has the imaginable to physique momentum done the remainder of the twelvemonth into mid-terms, the expert tells investors successful a probe note. For the company, the steadfast notes that portion it has somewhat tempered its eventual expectations connected Viridian’s commercialized accidental successful TED, with Veli’ peaking astatine $630M successful 2031, and Ele’ peaking astatine $1.14B successful 2035, the statement is apt to proceed arsenic investors and adjacent docs equilibrium the real-world inferior of Viridian’s reduced therapeutic load worth prop with Amgen’s (AMGN) existing doc, patient, and payer relationships and existing commercialized infrastructure and support, Truist added.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Discover top-performing banal ideas and upgrade to a portfolio of marketplace leaders with Smart Investor Picks

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected VRDN:

Disclaimer & DisclosureReport an Issue

Viridian Therapeutics terms people lowered to $31 from $37 astatine Wedbush
3 Best Trending Stocks, According to Analysts – 4/7/2026
Viridian Therapeutics terms people lowered to $30 from $42 astatine RBC Capital
Viridian Therapeutics removed from Best Ideas List astatine Wedbush
Viridian: Pullback Seen arsenic Overdone arsenic Veligrotug Convenience and TED Portfolio Underscore Buy Rating

Read Entire Article